Drug Profile
OGD 202
Alternative Names: Anti-GD2-RLI - OGD2 Pharma; ICK IL-15 - OGD2 Pharma; OGD202Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator OGD2 Pharma
- Class Cytokines; Immunoconjugates; Interleukins
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 28 Jun 2016 Preclinical trials in Cancer in France (Parenteral)
- 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Monoclonal antibodies against OAcGD2 for the treatment of Cancer